REMSleep Holdings, Inc., developer of the FDA-cleared DeltaWave(TM) nasal pillow system, announced the full commercial launch of the DeltaWave product portfolio across all U.S. distribution channels, including durable medical equipment (DME) companies and institutional sales.
With expanded FDA 510(k) clearance secured on January 15 and Medicare PDAC coding approved for every product configuration on January 21, the final regulatory prerequisites for nationwide distribution are now in place.
What’s in the Portfolio
The DeltaWave Nasal Pillow System is built around a patented Direct Airflow Technology – a design that reduces the pressure and airflow sensation patients feel at the nasal interface. It’s a unique engineering design with real clinical impact: patients who feel less effects of pressure tend to stay on therapy longer. That’s the therapy compliance problem this product was built to solve.
The full commercial portfolio includes:
- Starter Kit – includes all three nasal pillow sizes in a single package, simplifying initial patient setup and fitting
- Single Pillow Systems – ideal for resupply
- Nasal Interface (without headgear) – an additional resupply configuration
- Full Accessories Suite – complete range of replacement components
The PDAC coding approvals cover all of these configurations for Medicare and private-payor billing. DME providers now have the codes, the inventory access, and the clinical rationale to bring DeltaWave into their product mix.
What This Means for the Market
CPAP compliance is a persistent problem in sleep medicine. Somewhere between 30 and 50 percent of patients prescribed therapy abandon it within the first year, and mask discomfort is consistently cited as a top reason. DME providers deal with this daily – patients calling to return masks, asking for alternatives, or simply disappearing from follow-up.
DeltaWave’s positioning as a rescue mask alternative gives providers a clinically differentiated option when their standard formulary isn’t working. That’s a concrete value proposition that has real-world application.
The expanded clearance also opens institutional channels – hospitals, long-term care facilities, rehabilitation centers, and sleep labs – that weren’t accessible under the original 510(k) language. Those channels tend to introduce the solution to patients at the beginning of therapy.
Thomas Wood, CEO and Founder
“After years of funding this product personally through FDA, patents, clinical testing, and every operational hurdle you can imagine – it’s good to say we’re launching finally. Not ‘preparing to launch,’ not ‘targeting a launch’ – launching. The product works. The market needs it. The infrastructure is ready. Now we sell.”
Wood added: “DeltaWave was designed from day one to give patients a more comfortable breathing experience – so they stay on therapy and actually benefit from it. That design goal hasn’t changed. What’s changed is that we now have everything in place to put it in their hands at scale.”
Ordering and Availability
The DeltaWave Nasal Pillow System is available now through REMSleep’s direct sales channels. DME providers, physicians, and patients can reach the sales team at sales@remsleep.com or visit www.remsleep.com for product specifications, pricing, and ordering information.
Source: REMSleep Holdings
